Table 2.
Analysis of Western blots method and ELISA of 14-3-3 protein of CSF in 124 CJD patients and 99 patients with other neurological disorders and rapid progressive dementia
| disease | number | male | female | 14-3-3 γ | 14-3-3 all isoforms | ||||
|---|---|---|---|---|---|---|---|---|---|
| ELISA | WB | WB | |||||||
| average | SD | min | max | ||||||
| CJD | 124 | 69 | 55 | 263, 549 | 21, 525 | 135 | 75, 373 | 108/124 | 114/124 |
| DAT | 54 | 33 | 21 | 1, 537 | 751.2 | 0 | 2, 410 | 3/54 | 7/54 |
| CVD | 7 | 5 | 2 | 975.9 | 332.4 | 521 | 1, 51 2 | 0/7 | 2/7 |
| PD | 5 | 4 | 1 | 542.2 | 20.3 | 521 | 565 | 0/5 | 0/5 |
| PSP | 3 | 2 | 1 | 223.3 | 226.6 | 38 | 476 | 0/3 | 0/3 |
| FTLD | 2 | 1 | 1 | 425 | 236.2 | 258 | 592 | 0/2 | 0/2 |
| HD | 1 | 1 | 0 | 556 | 0. | 556 | 556 | 0/1 | 0/1 |
| CBD | 2 | 2 | 0 | 449.5 | 245.4 | 276 | 623 | 0/2 | 0/2 |
| ALS | 3 | 1 | 2 | 303.7 | 184.8 | 179 | 516 | 0/3 | 0/3 |
| limbic encephalitis | 2 | 1 | 1 | 4440.5 | 1935.4 | 3, 072 | 5, 809 | 2/2 | 2/2 |
| MELAS | 4 | 2 | 2 | 5, 069.5 | 222.7 | 4, 912 | 5, 227 | 4/4 | 4/4 |
| PCD/LEMS | 2 | 1 | 1 | 4, 387 | 217.8 | 4, 233 | 4, 541 | 2/2 | 2/2 |
| temporal epilepsy | 4 | 1 | 3 | 3, 356.8 | 1332.4 | 1, 530 | 4, 696 | 4/4 | 4/4 |
| MCI | 3 | 1 | 2 | 603 | 20.8 | 591 | 627 | 0/3 | 0/3 |
| Dementia, etiology unknown | 3 | 1 | 2 | 410.3 | 150.5 | 258 | 559 | 0/3 | 0/3 |
| healthy subject | 4 | 2 | 2 | 0 | 0 | 0 | 0 | 0/4 | 0/4 |
CJD: Creutzfeldt-Jakob disease, DAT: Dementia of Alzheimer's type, CVD: Cerebral Vascular Disorder, PD: Parkinson's disease, PSP: progressive supranuclear palsy, FTLD: frontotemporal lobular degeneration HD: Huntington's disease, CBD: corticobasal degeneration, ALS: amyotrophic lateral sclerosis, MELAS: Mitochondrial myopathy, Encephalopathy, Lactic Acidosis, Stroke-like episodes, PCD: paraneoplastic cerebellar degeneration, LEMS: Lambert-Eaton myasthenic syndrome, MCI: mild cognitive impairment,